Cost-Effectiveness (Ce) Analysis of Empagliflozin 25mg Versus Sitagliptin 100mg in the Treatment of Patients with type 2 Diabetes Mellitus (T2dm) when added to metformin (Met) from a Mexican Public Institutional Context
May 1, 2015, 00:00
10.1016/j.jval.2015.03.359
https://www.valueinhealthjournal.com/article/S1098-3015(15)00416-7/fulltext
Title :
Cost-Effectiveness (Ce) Analysis of Empagliflozin 25mg Versus Sitagliptin 100mg in the Treatment of Patients with type 2 Diabetes Mellitus (T2dm) when added to metformin (Met) from a Mexican Public Institutional Context
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00416-7&doi=10.1016/j.jval.2015.03.359
First page :
A61
Section Title :
Diabetes/Endocrine Disorders
Open access? :
No
Section Order :
1462